### **Neuromodulation: Capturing the Back**

### **Dr Paul Verrills**





metro spinal clinic

Disclosure: Travel support from Australian Chapter of INS

#### **Neuromodulation: Capturing the Back**



Transverse Tripole Arrays Multiple Independent Current Control

**Peripheral Nerve Stimulation** 

## **Transverse Tripolar Arrays**



#### Thanks to Vytas Rupinskas Sr. Mrktg Mgr. Leads & Accessories ANS

## **Science: Electrical Review**



## Data on Tripoles

- 1996: Struijk, Holsheimer. *Med & Biol Eng & Comput.*
- 1998: Struijk, Holsheimer et al. *IEE*E
- 1999: Slavin et al Stereotactic Functional Neurosurgery
- 2004: ANS introduces Tripole 8<sup>™</sup> Paddle
- 2005 INS: Feler presentation
- 2005 INS: Hale presentation
- 2006 ASRA: Caraway poster
- 2006 NANS: Miyazawa and Prager poster
- 2006 Neuromodulation: Oakley article MDT's TTS (Transverse Tripolar System)
- 2006: over 3000 units

## Science: Anatomy Key Points

- Where to target?<sup>1</sup>
- Fibres start lateral and then move more medial as you go up the cord
- Density of the large target fibres decreases as the layers go up<sup>2</sup>
- Back is a challenge: Target T8-T10<sup>1</sup>
  - 1. Barolat et al. *J Neurosurg*. 1993
  - 2. Feirabend et al. *Brain.* 2002



## **Science: Anatomical Review**

#### Lower Thoracic (approx. T9/T10)



#### A Midline Single Cathode Offers Preferential Dorsal Column Recruitment with Spinal Cord Stimulation

David Caraway et al, Medtronic

- Configuration that offers the best DC selectivity is transverse tripole.
- Cathodes placed off the midline results in poorer dorsal column selectivity due to proximity of cathode to the dorsal roots.
- The voltage (VDC) necessary to activate one DC fibre at the midline and on the border of the white matter and CSF is highest with the transverse guarded tripole
- Using transverse tripoles gives the best selection of DC to DR fibre activation.

### Guarded Cathode Arrays Allow Differential Spinal Cord Stimulation Effects

Gabi Miyazawa et al, Medtronic

Image: Note of the state of the st	
Initial         Initial <t< th=""><th>10.1</th></t<>	10.1
Group 0 Group 6	1
	+

### Guarded Cathode Arrays Allow Differential Spinal Cord Stimulation Effects

Gabi Miyazawa et al, Medtronic

- Transverse Tripole (Group E) provided:
  - the best recruitment of DC vs DR fibres
  - highest usage range
  - however higher voltages were required to activate the first DC fibre
- The 4-8-4 array offers new patterns for paraesthesia coverage.

Oakley, J.C. et al. Transverse Tripolar SCS: Results of an International Multicenter study. *Neuromodulation*. 2006:9(3);192-203.

- 8 centers, 56 patients, 41 implanted
- 20 chose IPG w/quad, 21 chose dual channel RF w/TTS

 VAS scores dropped more for patients with TTS (32%) than conventional polarity (16%)

Oakley Paper

 TTS (Transverse Tripolar Stim) Implant Lateral 0.5 mm wide x 10 mm long, Central 1.5 mm long x 4.5 mm wide, Lateral spacing 3 mm, Longitudinal spacing 2.25 mm



#### Oakley Paper

- "The system ... was noted to be very sensitive to ...physiologic midline."
- "The center electrode is 4.5 mm wide and if it is two or more millimeters off...it is over the dorsal root."
- "In finding the higher usage range ... we believe this indicates that the dorsal root fibres have an increased threshold as compared to dorsal column fibres due to the lateral anodal fields."

#### Oakley Paper

- No attempt was made to specifically assess low back coverage or relief
- Those observed to perceive paraesthesia in the low back, did not generally report pain relief
- No statistically significant difference in outcomes between the 2 implanted groups
- Between 53 61% reported "good" or "excellent" outcomes at 1 year

## How to achieve a Tripole

- Perc Tripole<sup>™</sup>: Two Quattrode<sup>®</sup> leads and an Octrode<sup>®</sup> lead
  - Can be done by interventional pain management specialists
  - Can be difficult to align all three leads
- Paddle Lead
  - Requires a surgeon
  - Requires a laminectomy



## ANS Tripole Family



## Lamitrode Tripole 8



## **Anodal Blocking**

Limit root stimulationFocused targeting



## Tripole<sup>™</sup> C Paddle Lead

















## Background

Study by: Gerald Hale, DO Tulsa, Oklahoma, USA

- 23 patients
  - Previous back surgery FBSS (96%)
  - Low-back & concurrent leg pain (96%)
  - Bilateral leg (4%)
- Psychological exam
- Successful trial
- Implanted Feb 2004–Feb 2005

## Methods

 Device – Tripole 8 (ANS) - Genesis IPG (ANS) Implanted by surgeon -MAC- Hemi-lamenectomy – Tip at T8 Initial programming in hospital

## Demographics

- Patients
- Female
- Male
- Mean age (range)
- Mean time in pain
- VAS (range)

23 100% 14 61% 9 39% 58.9 (42-73) 11.7 years 8.8 (7-10)

## Paraesthesia Coverage



## Back Coverage by Dermatome



## VAS



## Patient Satisfaction



## **Overall Pain Relief**



Measured at second session

## Quality of Life



## Would choose to do procedure again?



Measured at second session

## Conclusion

- Provided broad coverage for the majority of patients
- Effectively relieved pain in high percentage of patients with low-back and concurrent leg pain
- Provided coverage at a higher dermatomal level compared to traditional leads
- Significant decrease in VAS scores
- Improved patient satisfaction and QOL ratings
- Prospective multi-center study needed to further validate

## **Spinal Cord Stimulation:**

#### Multicentre SCS for Axial Low Back

259 Enrolled through 25 sites
mean age 56 (+/-14)
50.4% female
Duration – mean 14 years
226 trials – 76% positive
Trial VAS man 6.6 pre to 3.9 (P < 0.0001)</li>
Average VAS reduction – 40%
159 implants

Sponsored by Boston ScientificAAPM 2007 Thacker et al



Pain

## **Spinal Cord Stimulation:**

### Paraesthesia Coverage of Back

15 patients implanted Boston Scientific Precision™ SCS System

- Metro Spinal Clinic



metro spinal clinic

Pain

## Phone survey: Stimulation coverage of back pain

areas

# First 15 SCS patients implanted for back pain at Metro Spinal Clinic

Female Male	11 4		
	mean	SD	min max
Age (years)	51	14	27 72
Days implanted	143	86	13 258













## Programming

Programming	Mean	SD	Min Max
Days since last programming	87	58	9 183
Days of programmer data*	55	67	1 238
Usage (hours/day)	17.4	6.2	4.7 23.6
Programs (Number used/day)	1.6	0.4	1.0 2.7

\*IPG collects and stores program usage and battery data every 4 hours, which is then downloaded to the Clinician's Programmer at each visit.

- Each **Patient** can have 1-4 "Programs" to change as needed with the Remote Control
- Each **Program** can have 1-4 "Stimulation Areas" delivering stimulation pulses sequentially
- Each **Area** can have different electrode configurations, current amplitude, pulse width and frequency
- Each of the **16 electrodes** can be independently controlled to deliver a fixed percentage of the total anodal (+ve) or cathodal (-ve) current

#### Pt 8 SB



Most recent programs for these patients consisting of 1-4 Areas. Each electrode can be programmed to deliver 0-100% of total current.

#### Pt 7 LG

1 BODY Level : 6.7 mA Pulse Width : 300 uS Rate : 60 Hz



#### Pt 10 CB

low back Level : 4.8 mA Pulse Width : 550 uS Rate : 60 Hz



r)back Level : 5.4 mA Pulse Width : 550 uS Rate : 60 Hz



Iwr back Level : 7.5 mA Pulse Width : 550 uS Rate : 60 Hz



#### Pt 11 IJ



#### Pt 4 PP

1 BODY Level : 7.5 mA Pulse Width : 550 uS : 60 Hz Rate



r)LEG GO	
Level	:5 <i>mA</i>
Pulse Width	: 550 uS
Rate	: 60 Hz



R)leg+ Level : 5.7 mA Pulse Width : 550 uS : 60 Hz Rate

+ <sup>46</sup>
- 100
+ 54

top L) I	
Level	: 4.6 mA
<b>Pulse Width</b>	า : <i>550 น</i> S
Rate	: 60 Hz

- 71	- <sup>29</sup>
+ <sup>51</sup>	+ 19
+ 12	+ 4
+ 12	$+^{2}$

## Pulse Width: Background



Strength-duration curve for large and small nerve fibres

## Pulse Width: Background

- In the superficial DC, ~85% of fibres are smaller than 7 μm and <1% are larger than 10 μm (Feirabend et al, 2004).
- Longer PW values promote the activation of smaller diameter fibres relative to larger diameter fibres, as found in other neurostimulation applications (Gorman and Mortimer, 1983).
- In SCS, longer PW may increase the number of fibres activated and thereby increase the likelihood of generating paresthesia in broader dermatomal regions (Meyerson, 1997).



<u>Source:</u> Feirabend et al, *Brain* 2004

## **Pulse Width: Discussion**

- Paresthesia
   Coverage with PW
   More DC activation
  - Hypothesis:
    - Fibre size and density are smaller in more medial DC's \*
    - Increased PW allows greater recruitment of smaller fibres



\*Feirabend et al, Brain 2004

## Pulse Width: Background



Source: Gould B, Bradley K. Pain Medicine. 2006; 7(2): 205.

Peripheral Nerve Field Stimulation: A novel treatment in chronic low back pain and failed back surgery syndrome

> AIM: to evaluate the usefulness of peripheral nerve field stimulation as a treatment option for patients with chronic low back pain and failed back surgery syndrome.

## MATERIALS & METHOD

## • n=13

- 11 met the diagnostic criteria for failed back surgery syndrome (FBSS)
- Questionnaire used to assess outcomes including:
  - pain indices, post-operative changes in analgesic use and the overall level of patient satisfaction
  - questionnaire response rate 93% (13/14)
- Average follow-up time = 7 months.

### DEMOGRAPHICS

- Mean patient age: 61.3 ±10.4 (range 42-80 years)
- 7 females / mean age 56 ±7 years
- 6 males /mean male age 67±11

## SELECTION CRITERIA

- Clear low back pain with a neuropathic or combined somatic (nociceptive) & neuropathic pain component.
- Failure to respond to other conservative treatments (including medications, psychological therapies, rehabilitation and pain management programs).
- Previous failure of, or ineligibility for surgical procedures (including fusions or radiofrequency neurotomy (RFN)).
- Psychological clearance (including drug addictions, major depression and similar severe disorders that might impact on successful treatment).
- Clearly defined, discrete focal area of pain, e.g. commonly a "band" of approximately 1 to 2 hands spans over the low back.
- Informed consent

### **POSITIVE TRIAL**

 55% of clinic patients responded positively to the neuromodulation trial period and proceeded to permanent implantation of Peripheral Stimulator

## POSITIVE TRIAL CRITERIA

- Patients proceeding beyond the trial to implantation of PNFS must meet the following criteria:
  - 1. Defined as halving of original pain levels, with stimulation covering most of the painful area.
  - 2. Report a reduction in reliance on analgesics.
  - **3.** Report an improvement in 'valued' activities of daily living (ADL).

#### PERCENTAGE PAIN RELIEF of ORIGINAL PAIN







Figure 2. Patient pain relief as a result of PNFS, where pain relief is expressed as the mean VAS recorded both pre and post PNFS.

#### ANALGESIC USE



Figure 3. Patient need for medication following PNFS.

### PATIENT SATISFACTION





- Where PNS for chronic low back and FBSS was successful, it improved pain by an average of 4.18 VAS points.
- An overall improvement of 50.06% (±21.8%) on original pain levels was observed after PNFS.
- More than half the patients reported a decrease in analgesic use after PNFS.
- More than 75% patients were satisfied with the procedure.
- This study demonstrates PNS is a safe, reversible and effective treatment option for patients suffering chronic low back pain.